

**Brilliant Violet 711® anti-human CD73 (Ecto-5'-nucleotidase)**

**Catalog # / Size:** 2320130 / 100 tests  
2320125 / 25 tests

**Clone:** AD2

**Isotype:** Mouse IgG1, κ


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 711™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Workshop Number:** V B-CD73.3

**Concentration:** Lot-specific




Human peripheral blood lymphocytes were stained with CD3 PE and CD73 (clone AD2) Brilliant Violet 711™ (top) or mouse IgG1, κ Brilliant Violet 711™ isotype control (bottom).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be

resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Additional reported applications (for the relevant formats) include:immunofluorescence3.

**Application References:** 1. Nakamura T, *et al.* 1993. *J. Immunol.* 151:6933.  
2. Liao J, *et al.* 2011. *J Endod.* 37:1217. [PubMed](#)  
3. Touboul C, *et al.* 2013. *J. Transl. Med.* 11:28. (IF)

---

**Description:** CD73 is a 70 kD glycoposphatidylinositol (GPI)-linked 5'-nucleotidase, which is also known as ecto-5'-nucleotidase. It converts adenosine monophosphate (AMP) to adenosine. CD73 is expressed on subsets of T and B cells, mesenchymal stem cells, follicular dendritic cells, endothelial cells, and epithelial cells. It has been reported that CD73 costimulates T cell activation, and mediates adhesion of lymphocytes to follicular dendritic cells and endothelial cells.

**Antigen References:** 1. Zola H, *et al.* 2007. *Leukocyte and stromal Cell Molecules:the CD Markers.* A John Wiley & Sons Inc, Publication.  
2. Airas L and Jalkanen S, *et al.* 1996. *Blood* 88:1755.  
3. Gutensohn W, *et al.*